Human PD-1, Tag Free, Full Length (PD1-HC214) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Leu 288 (Accession # NP_005009.2).
N-terminal Sequence Analysis: Leu 25
This protein carries no "tag".
The protein has a calculated MW of 29.3 kDa. The protein migrates as 29-70 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>92% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in 50 mM tris, 100 mM glycine, pH7.5 with detergent. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
No activity loss is observed after storage at:
- 4-8°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Human PD-1, Tag Free, Full Length on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 92%.
- Lane1, Negtive control, 10 μg HEK 293 cell lysate
- Lane2, 10 ng rhPDCD1 full length protein in 10 μg HEK293 lysate
- Lane3, 100 ng rhPDCD1 full length protein in 10 μg HEK293 lysate
- Lane4, Positive control, 100 ng rhPDCD1 protein (Catalog # PD1-H5221) in 10 μg HEK293 lysate
Detection by anti-human PDCD1 mAb (4H1)
Programmed cell death protein 1 (PD-1) is also known as CD279 and PDCD1, is a type I membrane protein and is a member of the extended CD28/CTLA-4 family of T cell regulators. PDCD1 is expressed on the surface of activated T cells, B cells, macrophages, myeloid cells and a subset of thymocytes. PD-1 has two ligands, PD-L1 and PD-L2, which are members of the B7 family. PD-L1 is expressed on almost all murine tumor cell lines, including PA1 myeloma, P815 mastocytoma, and B16 melanoma upon treatment with IFN-γ. PD-L2 expression is more restricted and is expressed mainly by DCs and a few tumor lines. PD1 inhibits the T-cell proliferation and production of related cytokines including IL-1, IL-4, IL-10 and IFN-γ by suppressing the activation and transduction of PI3K/AKT pathway. In addition, coligation of PD1 inhibits BCR-mediating signal by dephosphorylating key signal transducer. In vitro, treatment of anti-CD3 stimulated T cells with PD-L1-Ig results in reduced T cell proliferation and IFN-γ secretion. Monoclonal antibodies targeting PD-1 that boost the immune system are being developed for the treatment of cancer.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
- (1) Ishida Y., et al., 1992, EMBO J. 11 (11): 3887–95.
- (2) Blank C., et al., 2007, Cancer Immunol. Immunother. 56 (5): 739–45.
- (3) Agata Y., et al., 1996, Int. Immunol. 8 (5): 765–72.
- (4) Freeman GJ., et al., 2000, J. Exp. Med. 192 (7): 1027–34.
- (5) Latchman Y., et al., 2001, Nat. Immunol. 2 (3): 261–8.
- (6) Yamazaki T., et al., 2002, J. Immunol. 169 (10): 5538–45.